GenSight Biologics S.A.

EPA:SIGHT.PA

0.39 (EUR) • At close September 16, 2024
Bedrijfsnaam GenSight Biologics S.A.
Symbool SIGHT.PA
Munteenheid EUR
Prijs 0.39
Beurswaarde 41,058,228
Dividendpercentage 0%
52-weken bereik 0.282 - 0.919
Industrie Biotechnology
Sector Healthcare
CEO Dr. Bernard Gilly Ph.D.
Website https://www.gensight-biologics.com

An error occurred while fetching data.

Over GenSight Biologics S.A.

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010),

Vergelijkbare Aandelen

Fermentalg SA logo

Fermentalg SA

FALG.PA

0.56 EUR

Eurofins-Cerep SA logo

Eurofins-Cerep SA

ALECR.PA

21,400 EUR

Sequana Medical NV logo

Sequana Medical NV

SEQUA.BR

0.902 EUR

MDxHealth SA logo

MDxHealth SA

MDXH.BR

3.02 EUR

MaaT Pharma SA logo

MaaT Pharma SA

MAAT.PA

7.2 EUR

Novacyt S.A. logo

Novacyt S.A.

ALNOV.PA

0.776 EUR

OSE Immunotherapeutics SA logo

OSE Immunotherapeutics SA

OSE.PA

6.58 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)